- Home
- DSGN vs QTRX Comparison
DSGN vs QTRX Comparison
Compare DSGN & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- QTRX
- Stock Information
- Founded
- DSGN 2017
- QTRX 2007
- Country
- DSGN United States
- QTRX United States
- Employees
- DSGN N/A
- QTRX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- DSGN Health Care
- QTRX Industrials
- Exchange
- DSGN Nasdaq
- QTRX Nasdaq
- Market Cap
- DSGN 208.9M
- QTRX 241.2M
- IPO Year
- DSGN 2021
- QTRX 2017
- Fundamental
- Price
- DSGN $6.54
- QTRX $5.66
- Analyst Decision
- DSGN
- QTRX Hold
- Analyst Count
- DSGN 0
- QTRX 4
- Target Price
- DSGN N/A
- QTRX $11.75
- AVG Volume (30 Days)
- DSGN 173.8K
- QTRX 518.4K
- Earning Date
- DSGN 11-06-2025
- QTRX 11-11-2025
- Dividend Yield
- DSGN N/A
- QTRX N/A
- EPS Growth
- DSGN N/A
- QTRX N/A
- EPS
- DSGN N/A
- QTRX N/A
- Revenue
- DSGN N/A
- QTRX $125,784,000.00
- Revenue This Year
- DSGN N/A
- QTRX N/A
- Revenue Next Year
- DSGN N/A
- QTRX $37.89
- P/E Ratio
- DSGN N/A
- QTRX N/A
- Revenue Growth
- DSGN N/A
- QTRX N/A
- 52 Week Low
- DSGN $2.60
- QTRX $4.05
- 52 Week High
- DSGN $7.77
- QTRX $15.67
- Technical
- Relative Strength Index (RSI)
- DSGN 54.51
- QTRX 59.03
- Support Level
- DSGN $5.88
- QTRX $5.01
- Resistance Level
- DSGN $7.59
- QTRX $6.29
- Average True Range (ATR)
- DSGN 0.51
- QTRX 0.29
- MACD
- DSGN -0.06
- QTRX 0.07
- Stochastic Oscillator
- DSGN 37.42
- QTRX 53.12
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.